Garvan teams with Benitec in diabetes genetics project
16 December, 2002 by Pete YoungSydney's Garvan Institute of Medical Research is collaborating with gene silencing specialist Benitec to probe the role of specific genes in type 2 diabetes.
Q-Vis calls in administrators
16 December, 2002 by Pete YoungPerth biotech Q-Vis Ltd is in the hands of administrators Ferrier Hodgson after coming up empty-handed from a six-month search for a strategic partner with deep pockets.
Melbourne researchers discover malaria resistance mutation
11 December, 2002 by Melissa TrudingerA new pathway for the invasion of red blood cells by the malaria parasite Plasmodium falciparum has been discovered by Melbourne researchers based at the Walter and Eliza Hall Institute.
Learning about liver tissue
04 December, 2002 by Pete YoungA group of Australian researchers are pursuing ground-breaking work on receptors in muscle tissue which play an unexpectedly important part in regulating cholesterol levels.
Australian HIV vaccine trial touted for 2003
03 December, 2002 by Melissa TrudingerA public consortium of researchers is hoping to get permission to start a Phase I clinical trial of a new HIV vaccine early in the new year.
Peptech MD moves to sweeten $8.9m loss
03 December, 2002 by Graeme O'NeillPeptech managing director Stephen Kwik is accentuating the positives after Peptech reported an after-tax loss of $AU8.9 million loss in the 12 months to September, after a $AU32.7 million net profit in the previous year.
Researchers get closer to malaria vaccine
02 December, 2002 by Pete YoungThe hunt for an anti-malaria vaccine is hotting up thanks to Australian researchers who have shown for the first time that T-cells can provide cell-based immunity in humans against the red blood cell stage of malaria.
Antisense Therapeutics placement beats expectations
02 December, 2002 by Melissa TrudingerAntisense Therapeutics has raised $500,000 over its expected $4 million in an oversubscribed share placement that closed two days earlier than originally planned.
Virax successfully completes HIV clinical trial
28 November, 2002 by Melissa TrudingerVirax has announced the successful completion of its Phase I/IIa trial for its HIV immune-based therapeutic VIR201, with the last of 34 patients completing the six-month series of injections and blood tests.
MHRI research identifies targets for psychiatric disease
28 November, 2002 by Melissa TrudingerHigh-throughput screening techniques are being used in a unique approach to studying the molecular causes of schizophrenia and bipolar disorder.
IVF community doubts clone doctor claims
27 November, 2002 by Pete YoungAustralia's IVF community is deeply sceptical of claims by Italian embryologist Severino Antinori that the first birth of a cloned human embryo will take place in early January.
AustCancer miffed by market reaction
25 November, 2002 by Pete YoungCancer vaccine developer Australian Cancer Technology is mystified and disappointed by negative share market reaction to positive news from human trials of its cancer vaccine, Pentrix.
CSL celebrates cervical cancer vaccine success
21 November, 2002 by Graeme O'NeillCancer research is all hard slog, a long journey of many small steps, punctuated all too rarely by a genuine leap forward -- like the one announced today by CSL and its partner, pharma giant Merck and Co.
Sirtex moves toward US target
21 November, 2002 by Melissa TrudingerSirtex Medical is on track to achieve its goal of rolling out its SIR-Spheres cancer treatment in ten US hospitals by the end of the year, according to CEO Colin Sutton, with the ninth centre at Emory University Hospital treating its first two patients last week.
UTS brings in American to head infectious disease institute
19 November, 2002 by Graeme O'NeillThe University of Technology, Sydney (UTS) has appointed eminent American parasitologist Prof Michael Wallach as director of its new Institute for the Biotechnology of Infectious Diseases.
